Last 23 quarters of trend data · Healthcare · Vaccines & Infectious Disease
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.53 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.30 | 0.81 | 0.79 | 0.71 | 1.92 | 3.41 | 3.38 | 22.54 | 11.67 | 10.39 | 6.32 | 11.05 | 4.96 | 5.19 | 7.58 | 6.31 | 3.43 | 4.43 | 3.14 | 3.56 | 3.64 |
| — | -76.3% | -76.5% | -96.9% | -83.6% | -67.2% | -46.5% | +104.0% | +135.4% | +100.0% | -16.6% | +75.0% | +44.7% | +17.3% | +141.5% | +77.4% | -5.9% | +54.6% | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 29.05 | 211.95 | 1266.10 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -270.8% | -29.7% | -27.4% | -35.4% | -55.3% | -76.4% | -146.9% | -169.7% | -92.6% | -87.5% | -82.1% | -118.9% | -61.4% | -59.8% | -46.0% | -38.2% | -38.2% | -26.9% | -23.1% | -19.7% | -31.2% |
| — | +61.1% | +81.4% | +79.1% | +40.3% | +12.6% | -78.9% | -42.7% | -50.9% | -46.3% | -78.5% | -211.5% | -60.7% | -122.1% | -98.9% | -93.9% | -22.6% | +39.5% | +59.4% | +51.3% | — | |
| ROA | -138.0% | -22.0% | -19.5% | -22.9% | -32.5% | -41.0% | -49.6% | -56.5% | -44.9% | -52.5% | -52.1% | -68.8% | -38.0% | -41.5% | -34.6% | -32.1% | -35.1% | -25.5% | -21.7% | -18.6% | -28.6% |
| — | +46.4% | +60.7% | +59.5% | +27.6% | +22.0% | +4.7% | +17.8% | -18.2% | -26.7% | -50.3% | -114.4% | -8.4% | -62.8% | -59.4% | -72.5% | -22.5% | +35.1% | +54.3% | +45.1% | — | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.18 | 3.88 | 3.78 | 3.18 | 2.47 | 2.38 | 1.93 | 1.19 | 1.80 | 2.09 | 2.93 | 2.53 | 2.22 | 3.06 | 3.56 | 4.55 | 9.26 | 19.43 | 17.89 | 15.71 | 21.04 |
| — | +63.2% | +96.0% | +167.0% | +37.2% | +13.9% | -34.2% | -53.0% | -18.8% | -31.8% | -17.8% | -44.3% | -76.0% | -84.3% | -80.1% | -71.0% | -56.0% | +113.8% | +211.9% | +130.2% | — | |
| Quick Ratio | 3.18 | 3.88 | 3.78 | 3.18 | 2.47 | 2.38 | 1.93 | 1.19 | 1.80 | 2.09 | 2.93 | 2.53 | 2.22 | 3.06 | 3.56 | 4.55 | 9.26 | 19.43 | 17.89 | 15.71 | 21.04 |
| — | +63.2% | +96.0% | +167.0% | +37.2% | +13.9% | -34.2% | -53.0% | -18.8% | -31.8% | -17.8% | -44.3% | -76.0% | -84.3% | -80.1% | -71.0% | -56.0% | +113.8% | +211.9% | +130.2% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACXP stock.
Acurx Pharmaceuticals, Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Acurx Pharmaceuticals, Inc.'s business trajectory between earnings reports.